ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
Dow Jones
38.239,66
0,40%
Euro vs US Dollar
1,06965
-0,04%
Bitcoin
62.898,83
-1,32%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Aurinia Pharmaceuticals Inc (AUPH)

  7. Aurinia Pharmaceuticals Inc (AUPH) News

AUPH Aurinia Pharmaceuticals Inc

4,9001
0,0301 (0,62%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Aurinia Pharmaceuticals Inc AUPH NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,0301 0,62% 4,9001 01:43:37
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
4,89 4,86 5,01 4,91 4,87
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
16.4.202416:48BWUPDATE: New Aurinia Presentation Details at the 2024 Bloom..
15.4.202412:00BWAurinia Pharmaceuticals to Release First Quarter Financial..
09.4.202412:00BWAurinia Will Attend 2024 Bloom Burton & Co. Healthcare..
07.3.202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:10EDGAR2Form 8-K - Current report
29.2.202414:30BWAurinia Receives Exemptive Relief from Canadian Securities..
27.2.202414:30BWAurinia to Participate in Upcoming Investor Healthcare..
22.2.202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202422:19EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
15.2.202412:16EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15.2.202412:06EDGAR2Form 8-K - Current report
15.2.202412:00BWAurinia Discloses 2023 Year-End Financial and Operational..
14.2.202421:27EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05.2.202414:30BWAurinia Pharmaceuticals to Release 2023 Fourth Quarter and..
05.1.202412:02EDGAR2Form 8-K - Current report
05.1.202412:00BWAurinia Provides Preliminary Unaudited Fourth Quarter and..
20.12.202312:00BWAurinia Submits IND Application to US Food & Drug..
13.11.202312:00BWAurinia Pharmaceuticals Announces Collaboration Partner..
07.11.202316:30BWAurinia Presents Breadth of Data from AURORA Clinical..
02.11.202323:00BWAurinia Presents Breadth of Data at ASN 2023 Demonstrating..
02.11.202311:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02.11.202311:01EDGAR2Form 8-K - Current report
02.11.202311:00BWAurinia Pharmaceuticals Reports Third Quarter and Nine..
26.10.202321:00BWAurinia Response in Support of 2023 Updated EULAR..
19.10.202316:31BWCORRECTING and REPLACING Aurinia Pharmaceuticals to Release..
19.10.202312:00BWAurinia Pharmaceuticals to Release Third Quarter Financial..
13.10.202318:00BWAurinia Pharmaceuticals Announces Presentations at American..
22.9.202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.9.202322:06EDGAR2Form 8-K - Current report
21.9.202312:00BWAurinia Board of Directors Appoints Dr. Robert T. Foster as..
21.8.202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.8.202322:11EDGAR2Form 8-K - Current report
21.8.202312:00BWAurinia Appoints Two New Board Directors with Deep..
03.8.202312:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03.8.202312:03EDGAR2Form 8-K - Current report
03.8.202312:00BWAurinia Pharmaceuticals Reports Second Quarter and Six..
20.7.202312:00BWAurinia Pharmaceuticals to Release Second Quarter Financial..
19.7.202318:05BWLong Term Phase 3 Data Published in Arthritis & Rheumatology..
06.7.202314:33EDGAR2Form PX14A6G - Notice of exempt solicitation submitted by..
03.7.202312:06EDGAR2Form 8-K - Current report
29.6.202322:05BWAurinia Board of Directors Announces Exploration of..
20.6.202315:00BWAurinia Showcases Three Oral Presentations for LUPKYNIS®..
01.6.202315:00BWLUPKYNIS® (voclosporin) Achieved Significantly Higher Renal..

Kürzlich von Ihnen besucht

NASDAQ
AUPH
Aurinia Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten